DURECT Corp (NASDAQ: DRRX) announced that it has obtained positive results from a multi-dose Phase 1 clinical trial with an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE